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Abstract
Ovarian cancer remains the most lethal gynecologic malig-
nancy in the United States. Although many patients with
advanced-stage disease initially respond to standard combi-
nations of surgical and cytotoxic therapy, nearly 90% develop
recurrence and inevitably die from the development of
chemotherapy-resistant disease. The discovery of novel and
effective therapy against chemotherapy-resistant/recurrent
ovarian cancer remains a high priority. Using expression
profiling, we and others have recently found claudin-3 and
claudin-4 genes to be highly expressed in ovarian cancer.
Because these tight junction proteins have been described as
the low- and high-affinity receptors, respectively, for the
cytotoxic Clostridium perfringens enterotoxin (CPE), in this
study we investigated the level of expression of claudin-3
and/or claudin-4 in chemotherapy-naı¨ve and chemotherapy-
resistant primary human ovarian cancers as well as their
sensitivity to CPE treatment in vitro . We report that 100%
(17 of 17) of the primary ovarian tumors tested overexpress one
or both CPE receptors by quantitative reverse transcription-
PCR. All ovarian tumors showed a dose-dependent cytotoxic
effect to CPE in vitro. Importantly, chemotherapy-resistant/
recurrent ovarian tumors were found to express claudin-3 and
claudin-4 genes at significantly higher levels when compared
with chemotherapy-naı¨ve ovarian cancers. All primary ovarian
tumors tested, regardless of their resistance to chemother-
apeutic agents, died within 24 hours to the exposure to
3.3 Mg/mL CPE in vitro. In addition, we have studied the
in vivo efficacy of i.p. CPE therapy in SCID mouse xenografts
in a highly relevant clinical model of chemotherapy-resistant
freshly explanted human ovarian cancer (i.e., OVA-1).
Multiple i.p. administration of sublethal doses of CPE every
3 days significantly inhibited tumor growth in 100% of mice
harboring 1 week established OVA-1. Repeated i.p. doses of
CPE also had a significant inhibitory effect on tumor
progression with extended survival of animals harboring
large ovarian tumor burdens (i.e., 4-week established OVA-1).
Our findings suggest that CPE may have potential as a novel
treatment for chemotherapy-resistant/recurrent ovarian
cancer. (Cancer Res 2005; 65(10): 4334-42)
Introduction
Ovarian carcinoma remains the cancer with the highest
mortality rate among gynecologic malignancies in the United
States (1). Because of the insidious onset of the disease and the lack
of reliable screening tests, two thirds of patients have advanced
disease when diagnosed. Although many patients with dissemi-
nated tumors respond initially to standard combinations of
surgical and cytotoxic therapy, nearly 90% will develop recurrence
and inevitably succumb to the development of chemotherapy-
resistant disease (2). The identification of novel ovarian tumor
markers for early detection of the disease as well as the
development of effective therapy against chemotherapy-resistant/
recurrent ovarian cancer remains a high priority.
Our group as well as others have recently used high-throughput
technologies, such as high-density oligonucleotide and cDNA
microarrays, to analyze ovarian cancer genetic fingerprints (3–13).
Among the several candidate target genes identified, genes
encoding tight junction (TJ) proteins claudin-3 and claudin-4 were
consistently found as two of the most highly up-regulated genes in
ovarian carcinoma (3–5). Although the exact function of claudin-3
and claudin-4 overexpression in ovarian cancer is still unclear,
these proteins have recently been shown to represent the natural
receptors for Clostridium perfringens enterotoxin (CPE) and to be
the only family members of the transmembrane tissue-specific
claudin proteins capable of mediating CPE binding and cytolysis
(14, 15). CPE is a single polypeptide of 35 kDa comprised of 319
amino acids that is associated with C. perfringens type A food
poisoning, the second most commonly reported food-borne illness
in the United States (16). CPE triggers lysis of epithelial cells
through interaction with claudin-3 and claudin-4, with resultant
initiation of massive permeability changes, osmotic cell ballooning,
and lysis (14–16). Mammalian cells that do not express either
claudin-3 and/or claudin-4 fail to bind CPE and are not susceptible
to CPE cytotoxicity (16). The CPE structure/function relationship
has been extensively investigated, mainly by characterizing the
functional properties of enterotoxin fragments and point mutants
(17–19). The CPE290-319 COOH-terminus fragment is sufficient
for high affinity binding to target cell receptor and small complex
formation, although this fragment is incapable of initiating large
complex formation and cytolysis. Furthermore, the CPE290-319
COOH-terminus fragment inhibits cytolysis of susceptible target
cells by full-length CPE. Residues 45 to 116 of CPE are essential for
large complex formation and cytotoxicity, whereas deletion of the
NH2 terminus generates a CPE45-319 fragment with enhanced
large membrane complex formation and cytotoxic activity.
In this study, we have quantified by real-time PCR the ex-
pression levels of claudin-3 and claudin-4 receptors in several
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chemotherapy-naı¨ve and chemotherapy-resistant freshly explanted
ovarian tumors. In addition, we have tested the ability of CPE to
kill chemotherapy-sensitive and chemotherapy-resistant ovarian
cancers overexpressing claudin-3 and/or claudin-4 in vitro . Finally,
we have studied the in vivo efficacy of CPE therapy in SCID mouse
xenografts in a highly relevant clinical model of chemotherapy-
resistant freshly explanted human ovarian cancer (i.e., OVA-1).
Here, we report for the first time that chemotherapy-resistant/
recurrent ovarian tumors highly overexpress the claudin-3 and/or
claudin-4 receptors and that these chemotherapy-resistant tumors
are highly sensitive to CPE treatment in vitro . More importantly,
we report that in vivo therapy with repeated i.p. injections of
sublethal doses of CPE induces long-term survival of the majority
of animals harboring 1 week established chemotherapy-resistant
ovarian disease and extended survival of animals harboring a large
tumor burden of chemotherapy-resistant ovarian cancer (i.e.,
4 weeks established xenografts). CPE-mediated therapy may thus
represent a novel, potentially highly effective strategy for the
treatment of ovarian cancer resistant to chemotherapy as well as
other biologically aggressive human tumors overexpressing
claudin-3 and/or claudin-4 (3, 4, 20, 21).
Materials and Methods
Cloning and purification of NH2-terminus His-tagged Clostridium
perfringens enterotoxin. C. perfringens strain 12917 obtained from
American Type Culture Collection (Manassas, VA) was grown from a
single colony and used to prepare bacterial DNA with the InstaGene kit
according to manufacturer’s directions (Bio-Rad Laboratories, Hercules,
CA). The bacterial DNA fragment encoding full-length CPE gene (Genbank
M98037) was PCR amplified (primer 1, 5V-CGC CAT ATG ATG CTT AGT
AAC AAT TTA AAT-3V; primer 2, 5V-GAT GGA TCC TTA AAA TTT TTG AAA
TAA TAT TG-3V). The PCR products were digested with the restriction
enzymes NdeI/BamHI and cloned into a NdeI/BamHI–digested pET-16b
expression vector (Novagen, Madison, WI) to generate an in-frame NH2-
terminus His-tagged CPE expression plasmid, pET-16b-10xHIS-CPE. His-
tagged CPE toxin was prepared from pET-16b-10xHIS-CPE transformed
Escherichia coli M15. Transformed bacteria were grown at 37jC to 0.3 to
0.4 absorbance at 600 nm, after which CPE protein expression was induced
overnight with 1 mmol/L isopropyl h-D-thio-galactoside, and the cells
harvested, resuspended in 150 mmol/L NaH2PO4, 25 mmol/L Tris-HCL, and
8 mol/L urea (pH 8.0) buffer, and lysed by centrifugation at 10,000 rpm for
30 minutes. The fusion protein was isolated from the supernatant on a
Poly-Prep Chromatography column (Bio-Rad). His-tagged CPE was washed
with 300 mmol/L NaH2PO4, 25 mmol/L Tris-HCl, and 10 mol/L urea
(pH 6.0), and eluted from the column with 200 mmol/L NaH2PO4, 25 mmol/L
Tris-HCl, and 8 mol/L urea (pH 6.0). To reduce the level of endotoxin from
His-tagged CPE protein, 10 washings with ice-cold PBS with Triton X-114
( from 1% to 0.1%) and 10 washings with ice-cold PBS alone were done.
Dialysis (M r 3,500 cutoff dialysis tubing) against PBS was done overnight.
Purified CPE protein was then sterilized by 0.2 Am filtration and frozen
in aliquots at 70jC.
Primary and established cell lines. Fresh human ovarian cancer cell
lines (i.e., 11 chemotherapy-naı¨ve tumors generated from samples obtained
at the time of primary surgery and six chemotherapy-resistant tumors
obtained from samples collected at the time of tumor recurrence) and five
established ovarian cancer cell lines (UCI 101, UCI 107, CaOV3, OVACAR-3,
and OVARK-5) were evaluated for claudin-3 and claudin-4 expression by
real-time PCR. Patient characteristics from which primary specimens were
obtained are depicted in Table 1. Three of the six ovarian tumor specimens
found resistant to chemotherapy in vivo including OVA-1, a fresh ovarian
serous papillary carcinoma (OSPC) used to establish ovarian xenografts in
SCID mice (i.e., severely immunocompromised animals), were confirmed to
be highly resistant to multiple chemotherapeutic agents when measured as
percentage cell inhibition by in vitro extreme drug resistance assay
(Oncotech, Inc., Irvine, CA; ref. 22 and data not shown). UCI-101 and UCI-
107, two previously characterized and established human serous ovarian
cancer cell lines were kindly provided by Dr. Alberto Manetta (University
of California, Irvine, CA), whereas CaOV3 and OVACAR-3 were purchased
from American Type Culture Collection (Manassas, VA), and OVARK-5 was
established from a stage IV ovarian cancer patient as previously described
(23). Other control cell lines evaluated in the CPE assays included Vero
cells, normal ovarian epithelium (NOVA), normal endometrial epithelium,
normal cervical keratinocytes, primary squamous and adenocarcinoma
cervical cancer cell lines, Epstein-Barr transformed B lymphocytes, and
human fibroblasts. With the exception of normal cervical keratinocytes
and cervical cancer cell lines that were cultured in serum-free keratinocyte
medium, supplemented with 5 ng/mL epidermal growth factor and 35 to
50 Ag/mL bovine pituitary extract (Invitrogen, Grand Island, NY) at 37jC,
5% CO2, all other fresh specimens were cultured in RPMI 1640 (Invitrogen)
containing 10% fetal bovine serum (FBS; Gemini Bio-products, Calabasas,
CA), 200 units/mL penicillin, and 200 Ag/mL streptomycin, as previously
described (3, 23, 24). All samples were obtained with appropriate consent
according to Institutional Review Board guidelines. Tumors were staged
according to the International Federation of Gynecology and Obstetrics
operative staging system. Radical tumor debulking, including a total
abdominal hysterectomy and omentectomy, was done in all ovarian
carcinoma patients, whereas normal tissues was obtained from consenting
similar-age donors undergoing surgery for benign pathology. Tumors were
established after sterile processing of the samples from surgical biopsies as
previously described for ovarian and cervical carcinoma specimens
(3, 23, 24), whereas normal ovarian tissue was obtained by scraping
epithelial cells from the ovarian surface. Briefly, viable tumor tissue was
mechanically minced in RPMI 1640 to portions no larger than 1 to 3 mm3
and washed twice with RPMI 1640. The portions of minced tumor were
then placed into 250 mL flasks containing 30 mL enzyme solution (0.14%
collagenase Type I and 0.01% DNase 2,000 KU/mg; Sigma) in RPMI 1640,
and incubated on a magnetic stirring apparatus overnight at 4jC.
Enzymatically dissociated tumor was then filtered through 150 Am nylon
mesh to generate a single cell suspension. The resultant cell suspension
was then washed twice in RPMI 1640 plus 10% FBS. The epithelial nature
and the purity of epithelial tumor cultures was verified by immunohis-
tochemical staining and flow cytometric analysis with antibodies against
cytokeratin as previously described (3, 23, 24). RNA extraction was done at
Table 1. Characteristics of the patients
Patient Age Race Histology Grade Stage
OVA 1* 67 White OSPC G3 IV A
OVA 2 42 White OSPC G3 III B
OVA 3 61 White OSPC G3 III C
OVA 4* 60 White OSPC G3 III C
OVA 5 59 Afro-American OSPC G2/3 III C
OVA 6* 72 White OSPC G3 IV A
OVA 7* 63 White CC G3 III C
OVA 8* 74 Afro-American CC G3 III C
OVA 9* 68 White CC G3 III B
OVA 10* 77 White CC G3 III C
OVA 11* 65 White CC G3 III C
OVA 12R 81 White OSPC G3 IV A
OVA 13R 62 Afro-American OSPC G3 IV A
OVA 14R 58 White OSPC G3 III C
Abbreviations: OVA-R, patients with chemotherapy-resistant/recurrent
disease; CC, clear cell ovarian carcinoma.
*Patients fromwhichmatched chemotherapy-naı¨ve and chemotherapy-
resistant/recurrent disease were both available.
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a tumor cell confluence of 50% to 80% after a minimum of 2 to a
maximum of 10 passages in vitro . Only primary cultures that had at least
90% viability and contained >99% epithelial cells were used for sensitivity
to CPE in vitro .
RNA extraction and quantitative real-time PCR. RNA isolation from
primary and established cell lines was done using TRIzol Reagent
(Invitrogen) according to the manufacturer’s instructions. Quantitative
PCR was done with an ABI Prism 7000 Sequence Analyzer using the
manufacturer’s recommended protocol (Applied Biosystems, Foster City, CA)
to evaluate expression of claudin-3 and claudin-4 in all the samples. Each
reaction was run in triplicate. Briefly, 5 Ag total RNA from each sample were
reverse transcribed using SuperScript III first-strand cDNA synthesis
(Invitrogen, Carlsbad, CA). Five microliters of reverse transcribed RNA
samples ( from 500 AL of total volume) were amplified by using the TaqMan
Universal PCR Master Mix (Applied Biosystems) to produce PCR pro-
ducts specific for claudin-3 and claudin-4. The primers for claudin-3 and
claudin-4 were obtained from Applied Biosystems as Assay-on-Demand
products. Assay IDs were Hs00265816_s1 (claudin-3) and Hs00433616_s1
(claudin-4). The comparative threshold cycle (CT) method (PE Applied
Biosystems) was used to determine gene expression in each sample relative
to the value observed in the nonmalignant ovarian epithelial cells, using
glyceraldehyde-3-phosphate dehydrogenase (Assay-on-Demand Hs999-
99905_m1) RNA as internal controls.
Claudin-4 immunostaining of formalin-fixed tumor tissues. Ovarian
tumors were evaluated by standard immunohistochemical staining on
formalin-fixed tumor tissue for claudin-4 surface expression. Study blocks
were selected after histopathologic review by a surgical pathologist. The
most representative H&E-stained block sections were used for each
specimen. Briefly, immunohistochemical stains were done on 4-Am-thick
sections of formalin-fixed, paraffin-embedded tissue. After pretreatment
with 10 mmol/L citrate buffer (pH 6.0) using a steamer, they were incubated
with mouse anti–claudin-4 antibodies (Zymed Laboratories, Inc., San
Francisco, CA). Antigen-bound primary antibody was detected using
standard avidin-biotin immunoperoxidase complex (DAKO Corp., Carpin-
teria, CA). Cases with <10% staining in tumor cells were considered negative
for claudin expression. The positive cases were classified as follows
regarding the intensity of claudin-4 protein expression: +, weak staining; ++,
medium staining; and +++, intense staining. Subcellular localization
(membrane or cytoplasm) was also noted. Negative controls, in which the
primary antibodies were not added, were processed in parallel.
Clostridium perfringens enterotoxin treatment of cell lines and
trypan blue exclusion test. Tumor samples and normal control cells
were seeded at a concentration of 1  105 cells/well into six-well culture
plates (Costar, Cambridge, MA) with the appropriate medium. Adherent
tumor samples, fibroblasts, and normal epithelial control cell lines were
grown to 80% confluence. After washing and renewal of the medium,
CPE was added to final concentrations ranging from 0.03 to 3.3 Ag/mL.
After incubation for 60 minutes to 24 hours at 37jC, 5% CO2, floating
cells were removed and stored, and attached cells were trypsinized and
pooled with the floating cells. After staining with trypan blue, viability
was determined by counting the number of trypan blue–positive cells
and the total cell number.
SCID mouse tumor xenografts and Clostridium perfringens entero-
toxin treatment. C.B-17/SCID female mice 5 to 7 weeks old were obtained
from Harlan Sprague-Dawley (Indianapolis, IN) and housed in a pathogen-
free environment at the University of Arkansas for Medical Sciences. They
were given commercial basal diet and water ad libitum. The experimental
protocol for the use of these animals for these studies was approved by
the University of Arkansas for Medical Sciences Institutional Animal Care
and Use Committee. Animals were used to generate ovarian tumor
xenografts. The OVA-1 cancer cell line was injected i.p. at a dose of 5 
106 to 7.5  106 into C.B-17/SCID mice in groups of five. In the first
set of experiments (i.e., large ovarian tumor burden challenge), 4 weeks
after i.p. tumor injection, mice were injected i.p. with 5.0, 5.5, and 6.5 Ag
CPE dissolved in 1 mL sterile saline at 72-hour intervals. In a second
set of experiments, groups of five mice received 7.5 or 8.5 Ag of CPE i.p.
at 72-hour intervals 1 week after i.p. OVA-1 tumor injection at a dose of
5  106 tumor cells. All animals were observed twice daily and weighed
weekly and survival was monitored. In addition, groups of mice injected
i.p. at a dose of 5  106 to 7.5  106 OVA-1 tumor cells were killed at 1, 2, 3,
and 4 weeks for necropsy and pathologic analysis. The remaining animals
were killed and examined just before they died of i.p. carcinomatosis and
malignant ascites.
Statistics. Statistical differences in claudin-3 and claudin-4 expression
between chemotherapy-naı¨ve and chemotherapy-recurrent/resistant ovar-
ian tumors were tested using the Student’s t test. For the OVA-1 animal
model, survivals were plotted using Kaplan-Meier methods and compared
using the log-rank test. P < 0.05 was used for statistical significance.
Results
Claudin-3 and claudin-4 transcript levels in chemotherapy-
sensitive and chemotherapy-resistant ovarian tumors. We used
quantitative reverse transcription-PCR (qRT-PCR) assays to get
highly sensitive measurements of claudin-3 and claudin-4 expres-
sion in normal tissues and fresh and established human tumors.
Both claudin-3 and/or claudin-4 genes were highly expressed in all
primary ovarian cancers studied when compared with normal
ovarian epithelial cells as well as other normal cells or other
gynecologic tumors (Fig. 1). Of interest, established ovarian cancer
cell lines (UCI 101, UCI 107, CaOV3, OVACAR-3, and OVARK-5)
were found to express much lower levels of claudin-3 and/or
claudin-4 compared with primary ovarian tumors (Fig. 1). Finally,
claudin-3 and/or claudin-4 expression was extremely low in all
control tissues examined, including normal ovarian epithelium,
normal endometrial epithelium, normal cervical keratinocytes, and
normal human fibroblasts (Fig. 1).
Figure 1. qRT-PCR analysis of claudin-3 and claudin-4 expression. Y-axis, fold
induction relative to normal ovary expression (1 ). X-axis, each sample tested
for claudin-3 (A) and claudin-4 (B). The first 15 columns are normal ovarian
epithelium (1 -3), normal endometrial epithelium (4 -6), normal cervical
keratinocytes (7), primary squamous cervical cancer cell lines (8-10), primary
adenocarcinoma cervical cancer cell lines (11 -13), Epstein-Barr transformed B
lymphocytes (LCL ; 14), and human fibroblasts (15). The following 16 columns
are primary ovarian cancer cell lines (16-21, serous papillary ovarian cancers;
22 -26, clear cell ovarian tumors) and established serous ovarian cancer cell
lines (27-31 ; i.e., UCI 101, UCI 107, CaOV3, OVACAR-3, and OVARK-5).
Cancer Research
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When OSPC collected at the time of primary debulking surgery
(six cases) were compared for claudin-3 and/or claudin-4 receptor
expression to those collected at the time of tumor recurrence
after multiple courses of chemotherapy (six cases), chemotherapy-
resistant tumors were found to express significantly higher levels
of claudin-3 and/or claudin-4 receptors (P < 0.05; Fig. 2). Impor-
tantly, when three primary ovarian cancers naı¨ve to chemother-
apy were compared with recurrent ovarian cancers recovered
from the same patients following chemotherapy (i.e., matched
autologous tumor samples), chemotherapy-resistant tumors were
again found to express higher levels of claudin-3 and claudin-4
(Fig. 2).
Claudin-4 expression by immunohistology on ovarian serous
papillary carcinoma and normal ovarian epithelium tissue
blocks. To determine whether the high expression of the claudin-4
gene detected by qRT-PCR assays in primary ovarian cancer cell lines
is the result of a selection of a subpopulation of cancer cells present
in the original tumor or whether in vitro expansion conditions may
have modified gene expression, we did immunohistochemical
analysis of claudin-4 protein expression on formalin-fixed tumor
tissue from the uncultured primary surgical specimens from which
fresh ovarian cancers were derived. As shown in Table 2 and
representatively in Fig. 3 (right), moderate to heavy membranous
staining for claudin-4 protein expression was noted in all the cancer
specimens that overexpressed the claudin-4 transcript. In contrast,
negative or low staining was found in all the normal ovarian
epithelium tested by immunohistochemistry (Fig. 3; Table 2).
Effects of Clostridium perfringens enterotoxin on fresh
ovarian and cervical cancer cell lines and normal control
cells. On the basis of the high expression of claudin-3 and/or
claudin-4 on primary ovarian cancer cell lines previously reported
by us in a small group of patients (5), it was expected that ovarian
tumors expressing either claudin-3 or claudin-4 would be sensitive
to CPE-mediated lysis. However, it was important to show this
directly on fresh human ovarian carcinoma cells, particularly in a
clinically relevant setting of ovarian cancer disease for which
current salvage therapies are ineffective (i.e., chemotherapy-
resistant disease). For this reason, we examined short-term
in vitro primary cultures of ovarian carcinomas obtained either
from chemotherapy-naı¨ve patients (i.e., OVA-2, OVA-3, and OVA-5)
or patients heavily treated with different combinations of
chemotherapy (i.e., OVA-1, OVA-4, and OVA-6) and now with
disease progression after multiple chemotherapy regimens. The
Figure 2. qRT-PCR analysis of claudin-3 and claudin-4 expression in chemotherapy-naı¨ve versus chemotherapy-resistant/recurrent ovarian cancer. Y-axis, fold
induction relative to normal ovary expression. X-axis, each sample tested for claudin-3 and claudin-4. Top, chemotherapy-naı¨ve ovarian cancers = 6 OSPC samples
(1); columns, mean; bars, SE; chemotherapy-resistant/recurrent ovarian cancer = 6 OSPC samples (2); columns, mean; bars, SE; P < 0.05. Bottom, 1
(chemotherapy naı¨ve) and 2 (chemotherapy resistant) represent claudin-3 and claudin-4 expression in autologous matched OVA-1 tumors. 3 (chemotherapy naı¨ve)
and 4 (chemotherapy resistant) represent claudin-3 and claudin-4 expression in autologous matched OVA-4 tumors. 5 (chemotherapy naı¨ve) and 6
(chemotherapy resistant) represent claudin-3 and claudin-4 expression in autologous matched OVA-6 tumors.
Table 2. Claudin-4 staining
Patient Claudin-4 positivity
NOVA 1 1
NOVA 2 1
OVA 1 3
OVA 2 3
OVA 3 3
OVA 4 2
OVA 5 3
OVA 6 2
OVA 7 3
OVA 8 2
OVA 9 3
OVA 10 3
OVA 11 3
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sensitivity of these primary ovarian tumor cultures to CPE-
mediated cytolysis was tested along with an appropriate claudin-3
and claudin-4–expressing positive control (i.e., Vero cells),
established OSPC cell lines (OVARK-5, CaOV3, and OVACAR-3),
and negative controls that do not express detectable levels of
either claudin-3 or claudin-4. As shown in Fig. 4, regardless of their
sensitivity or resistance to chemotherapy, all ovarian tumors tested
were found sensitive to CPE-mediated cytolysis. The cytotoxic
effect was dose dependent and was positively correlated to the
levels of either claudin-3 or claudin-4 expression as tested by RT-
PCR in tumor samples. Importantly, although ovarian tumors
showed different sensitivities to CPE exposure, no ovarian cancer
was found viable after 24 hours exposure to CPE at the
concentration of 3.3 Ag/mL. In contrast, all normal controls tested
Figure 3. Representative immunohistochemical staining for claudin-4 on OVA-1 paraffin-embedded OSPC specimens (right ) and NOVA 1 specimen (left). NOVA 1
showed light membrane staining for claudin-4, whereas OVA-1 showed heavy cytoplasmic and membranous staining for claudin-4. Original magnification, 400.
Figure 4. Representative dose-dependent
CPE-mediated cytotoxicity of primary ovarian
cancers compared with positive control Vero cells
or negative controls (i.e., normal and neoplastic
cells) after 24 hours exposure to CPE. VERO,
positive control cells. OVA-1 to OVA-6, primary
ovarian tumors. OVARK-5 , CaOV3 , and
OVACAR-3, established serous ovarian tumors.
Norm CX, normal cervix keratinocytes. Fibroblast,
normal human fibroblasts. LCL, lymphoblastoid
B cells. PBL, normal peripheral blood lymphocytes.
CX1-3, primary squamous cervical cancer.
ADX1-3, primary adenocarcinoma cervical cancer.
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including ovarian epithelium, cervical keratinocytes, and mono-
nuclear cells as well as cervical cancer cell lines lacking claudin-3
or claudin-4 were not affected by CPE (Fig. 4).
Effect of Clostridium perfringens enterotoxin on chemotherapy-
resistant ovarian cancer cells in vivo. For in vivo confirmation of
our in vitro data, we have developed xenograft tumors in SCID mice
by i.p. injection with OVA-1, a primary ovarian tumor resistant to
multiple chemotherapeutic agents in vitro (by extreme drug
resistance assay) as well as in vivo. Primary OVA-1 tumor cells grew
progressively as numerous serosal nodules adherent to virtually all
intraabdominal organs (peritoneum, omentum, diaphragm, bowel,
liver, pancreas, and spleen) and exhibited the capacity for local tissue
invasion and formation of malignant ascites after 2 to 3 weeks from
injection. Tumors became evident by the second week as small
nodules on the omentum and continuously grew to form a confluent
omental mass by the time the animals died (i.e., mean survival 38
days after i.p. injection with 7.5  106 OVA-1 cells; Fig. 5). Necropsies
revealed massive hemorrhagic ascites and numerous tumor nodules,
measuring 1 to 8 mm in diameter, studding the entire peritoneal
surface and implanting the serosa of virtually all intraabdominal
organs (Fig. 5).
Previous toxicology studies in mice have reported 0.5 Ag/g
CPE administered i.p. to be a well tolerated and safe dose in
100% of the animals (i.e., 16.5 F 1.0 g male SW mice; refs. 25,
26). In contrast, some animals injected with 0.75 Ag/g died after
CPE injection and all animals injected with 1 Ag/g of CPE died
within 1 to 2 hours (25, 26). Our determination of maximum
tolerated dose in healthy female mice is consistent with these
observations (data not shown). In one experiment, groups of
mice harboring large ovarian tumor burden xenografts (i.e.,
4 weeks after OVA-1 tumor injection) were treated with repeated
i.p. CPE injections every 72 hours at three different doses (5.0,
5.5, or 6.5 Ag). Control mice harboring OVA-1 received saline
alone. CPE injections were well tolerated and no adverse events
were observed throughout the complete treatment protocol
either in control mice receiving CPE alone or CPE-treated mice
harboring large tumor burden. Mice harboring OVA-1 treated
with saline all died within 6 weeks from tumor injection with a
mean survival of 38 days (Fig. 6A). In contrast, animals treated
with multiple CPE injections survived significantly longer than
control animals did (P < 0.0001; Fig. 6A). The increase in
survival in the different groups of mice treated with the diverse
doses of CPE was clearly dose dependent, with the highest dose
injected (i.e., 6.5 Ag every 72 hours) found to provide the longer
survival (Fig. 6A). In another set of experiments, mice harboring
OVA-1 (a week after tumor injection with 5  106 cells) were
treated with i.p. CPE injections at a dose ranging from 7.5 to
8.5 Ag every 72 hours. Whereas mice harboring OVA-1 treated
with saline all died within 9 weeks from tumor injection (Fig.
6B), three of five (60%) and five of five (100%) of the mice
treated with multiple i.p. injections of CPE remained alive and
free of detectable tumor for the duration of the study period
(i.e., over 120 days, P < 0.0001).
Discussion
Several groups, including our own, have recently shown by gene
expression profiling that claudin-3 and claudin-4 are highly
overexpressed in primary ovarian carcinomas (3–5), the most
lethal gynecologic malignancy in the United States. These findings
imply that ovarian cancer refractory to standard treatment
modalities may be susceptible to CPE-based therapeutic
approaches. In this study, we have confirmed the high expression
of CPE receptors at both the RNA and protein levels in multiple
primary ovarian cancers and tested the sensitivity of tumor cells to
CPE treatment in vitro . Pharmacologic studies in ovarian cancer
patients have shown a marked therapeutic advantage to the i.p.
delivery of drugs and biologicals combined with a significant
reduction in systemic toxicity resulting from i.p. drug administra-
tion when compared with an identical dose of the drug given i.v.
(27). These clinical observations, combined with the fact that
ovarian cancer remains confined to the peritoneal cavity for much
of its natural history, suggest that i.p. administration of CPE in
human patients harboring recurrent ovarian cancer refractory to
Figure 5. Typical necropsy specimen from C.B-17/SCID
mice after 6 weeks from the i.p. injection of 7.5  106
viable OVA-1 cells. Note large omental tumor masses
and serosal implant on bowel mesentery (arrows ).
CPE-Mediated Therapy for Ovarian Cancer
www.aacrjournals.org 4339 Cancer Res 2005; 65: (10). May 15, 2005
Research. 
on March 4, 2018. © 2005 American Association for Cancercancerres.aacrjournals.org Downloaded from 
chemotherapy may result in reduced toxicity and better therapeu-
tic responses compared with an identical dose of CPE given i.v.
Accordingly, we have also conducted a careful evaluation of the
efficacy and toxicity of i.p. injection of CPE in vivo in a clinically
relevant animal model of chemotherapy-resistant ovarian tumor
xenografts.
Our studies showed that 100% (17 of 17) of the primary ovarian
cancer cell lines tested for claudin-3 and claudin-4 expression by
qRT-PCR overexpress either the high-affinity CPE receptor
(claudin-4) or the low-affinity CPE receptor (claudin-3). Of interest,
all the established ovarian cancer cell lines tested (UCI 101,
UCI 107, CaOV3, OVACAR-3, and OVARK-5) were found to express
much lower levels of claudin-3 and/or claudin-4 compared with
primary ovarian tumors. These data suggest that prolonged in vitro
culture may significantly alter claudin-3 and claudin-4 gene
expression in ovarian cancer. In addition, we have noticed a
consistent down-regulation of claudin-3 and claudin-4 expression
levels by qRT-PCR in the more advanced in vitro passages of
primary OSPC (data not shown). Thus, established ovarian cancer
cell lines may represent suboptimal models to evaluate the
potential of CPE-mediated therapy against ovarian cancer
in vitro as well as in vivo . Importantly, all primary ovarian tumors
evaluated, including those found to be resistant to chemotherapy
in vivo as well as in vitro , were found highly sensitive to CPE-
mediated killing in vitro . In this regard, although ovarian tumors
showed different sensitivity to CPE exposure, no ovarian cancer
was found viable after 24 hours exposure to CPE at the
concentration of 3.3 Ag/mL, a dose well tolerated by in vivo i.p.
administration of CPE in our animal model. This was in strong
contrast with the lack of sensitivity of normal ovarian epithelium as
well as other normal control cells to CPE-mediated cytolysis. These
findings are likely explained by a limited expression of claudin-3
and claudin-4 in normal epithelia compared with ovarian tumor
cells.
When the efficacy of multiple i.p. injection of sublethal doses of
CPE in vivo in a clinically relevant animal model of chemotherapy-
resistant ovarian tumor xenografts was tested, we found that
doses of CPE ranging from 5 to 8.5 Ag/mL were well tolerated, and
Figure 6. Survival of C.B-17/SCID mice after i.p.
injection of 5  106 to 7.5  106 viable OVA-1
tumor cells. Animals harboring 4-week (A ) and
1-week (B) established OVA-1 tumors were
injected i.p. with doses of CPE ranging from 5 to
8.5 Ag as described in Materials and Methods.
CPE was administered i.p. every 72 hours
until death or end of study. Mice were evaluated
on a daily basis and sacrificed when moribund.
In both studies, the log-rank test yielded
P < 0.0001 for the differences in survival.
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no adverse events were observed throughout the complete
treatment protocol either in control mice receiving CPE alone
or CPE-treated mice harboring small and large tumor burden.
These data show that CPE doses found effective in vitro to kill
ovarian tumor cells may be safely administered i.p. in mice
harboring ovarian cancer disease. More importantly, we found
that survival of mice harboring a large burden of chemotherapy-
resistant ovarian disease was significantly prolonged in a dose-
dependent manner by repeated i.p. injections of CPE. Finally,
when animals harboring 1 week OVA-1 xenografts were treated
with repeated i.p. injections of CPE, most of the mice remained
alive and free of detectable tumor for the duration of the study
(i.e., over 120 days). Collectively, these results provide strong
evidence to suggest that CPE-based therapy may have great
potential in the treatment of ovarian cancer patients refractory to
standard treatment modalities.
Despite the ability of CPE to effectively lyse chemotherapy-
resistant ovarian cancers in vitro as well as in vivo , the local
delivery of CPE for its clinical application in human patients faces
several limitations. Indeed, as with any foreign protein, multiple
administration of CPE may likely induce the development of
neutralizing antibodies in ovarian cancer patients, which may
prevent or reduce the efficacy of repeated CPE administrations.
Thus, although it has been previously observed that local defects in
immune responses are commonly detected in the peritoneal cavity
of advanced-stage ovarian cancer patients (28), and also that
elevated titers of antienterotoxin antibodies that arise following
CPE ingestion provide no protection for human subjects against
the effects of subsequent ingestion of CPE (29), careful studies need
to be done to accurately determine the presence and nature of the
immune response against CPE when administered by the i.p. route
in human patients.
Another potential problem with the i.p. administration of CPE in
ovarian cancer patients is the necessity for the toxin to distribute
evenly throughout the abdominal cavity to properly reach the
tumor tissue. This point is noteworthy because previous surgery
and subsequent adhesions, which can prevent homogenous fluid
distribution, might greatly reduce the efficacy of local CPE therapy.
In addition, because i.p. ovarian tumor plaques will likely receive
CPE by passive diffusion (i.e., typically only a few millimeters), the
inability of local CPE administration to deeply penetrate large solid
tumor masses may also reduce the efficacy of local CPE therapy in
patients harboring a large tumor burden. Taken together, these
points imply that local CPE administration would likely exert its
maximum benefit in patients with microscopic residual disease or
small-volume macroscopic cancer resistant to standard chemo-
therapeutic agents.
Although the clinical application of CPE faces several challenges,
it has also several potential advantages. Indeed, CPE-mediated
cytolysis requires only the single step of CPE binding to its
receptors and take place after only few minutes of tumor cell
exposure to toxic CPE concentrations. Thus, the simplicity and
rapidity of CPE-mediated cytolysis may result in increased efficacy,
reduced opportunity for the development of resistance, and the
possibility that high local concentrations of CPE may need to be
maintained for only a relatively short period of time. Furthermore,
because the efficacy of CPE therapy against chemotherapy-
resistant ovarian cancer xenografts has been shown in SCID mice,
it seems unlikely that the host immune system is required to play a
significant role in the in vivo efficacy of CPE therapy. This point is
noteworthy because several biological response modifiers pre-
viously used for the therapy of chemotherapy-resistant ovarian
cancer, including cytokines (30) and humanized monoclonal
antibodies (31), unlike CPE therapy, rely for most of their efficacy
on the activation of an uncompromised host immune system (32),
a major limitation when dealing with elderly ovarian cancer
patients heavily pretreated with multiple regimens of immunosup-
pressive chemotherapy.
In conclusion, we have shown that primary ovarian cancers
that have acquired in vivo resistance to chemotherapeutic drugs
may be susceptible to killing by CPE-mediated therapy in vitro
as well as in vivo . Taken altogether, our findings suggest that i.p.
CPE administration may have potential as a novel strategy
against chemotherapy-resistant/recurrent ovarian cancer. The
future design and implementation of phase I and phase II
clinical trials in patients harboring chemotherapy refractory
ovarian disease will determine the feasibility and validity of this
novel therapeutic approach.
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